ArticleFrontiers in oncology2026
Myeloma-derived exosomal circ_0002724 promotes osteoclastogenesis through a miR-4753-3p/IFIT1 and RANK axis in myeloma bone disease.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloma bone disease (MBD) is driven by excessive osteoclast activation and progressive bone destruction, but the role of exosomal circular RNAs (circRNAs) from myeloma cells remains unclear. Methods: Exosomes from U266 and MM1S cells were isolated and used to treat THP-1 cells. Osteoclast differentiation was assessed by TRAP staining and bone resorption assay. circRNA sequencing of U266 exosomes and MBD patient blood was performed to identify overlapping circRNAs. A ceRNA network was constructed using circBank and miRTarBase, combined with single-cell RNA-seq (GSE271107) to prioritize candidate target genes. Functional experiments included circ_0002724 knockdown/overexpression in U266 cells, exosomal transfer, TRAP, bone resorption, qRT-PCR, RNA-FISH/IF, dual-luciferase reporter assay, and immunohistochemistry of patient bone marrow biopsies. Results: U266-derived exosomes exhibited stronger osteoclast-inducing activity than MM1S-derived exosomes. Intersection analysis identified 14 common circRNAs, among which circ_0002724 showed the highest predicted miRNA-binding capacity and was significantly upregulated in THP-1 cells after exosome treatment. A circ_0002724-associated regulatory network identified miR-4753-3p, IFIT1, and RANK as potential downstream components. Single-cell analysis revealed that IFIT1 was highly expressed in MM osteoclast precursor cells and increased during osteoclast differentiation. Exosomal circ_0002724 was internalized by THP-1 cells; circ_0002724 knockdown reduced, whereas overexpression enhanced, TRAP-positive osteoclast formation and bone resorption activity, accompanied by altered RANK and IFIT1 expression. Dual-luciferase reporter assays supported the interactions between circ_0002724, miR-4753-3p, RANK, and IFIT1. Immunohistochemical analysis of patient biopsies demonstrated positive associations of circ_0002724, RANK, and IFIT1 with MBD severity. Conclusions: Myeloma-derived exosomal circ_0002724 promotes osteoclast activation and bone resorption and is associated with regulation of the miR-4753-3p/IFIT1/RANK network. These findings provide new insights into exosome-mediated tumor-bone microenvironment communication and suggest circ_0002724 as a potential biomarker and candidate therapeutic target for MBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.